Five Prime Therapeutics, Inc. announced the appointment of Bryan Irving, Ph.D., as executive vice president and chief scientific officer. Dr. Irving joined Five Prime in August 2017 as the vice president of research. Prior to joining Five Prime, Dr. Irving was at CytomX Therapeutics, where he most recently served as Vice President of Cancer Immunology, leading efforts to generate protease-activatable immunotherapies designed to mobilize anti-tumor immunity locally in the tumor microenvironment.